戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 em as well as on the material leading to ent-hydromorphone.
2 -day test sessions evaluated the response to hydromorphone (0, 6, and 18 mg intramuscular in random o
3 4526 to 3190), fentanyl (59%; 59 to 24), and hydromorphone (15%; 718 to 609), and increased for morph
4 ation and drug liking E(max) VAS score after hydromorphone 18 mg administration in 47 non-treatment-s
5 , oxycodone (23%; 1.6 to 2.0 million g), and hydromorphone (19%; 118,455 to 141,325 g), and a decreas
6 2), methadone (3.02; 95% CI, 2.45-3.73), and hydromorphone (2.03; 95% CI, 1.09-3.78).
7  benefit of combining dronabinol (10 mg) and hydromorphone (4 mg) for analgesia and improving physica
8 ebo; (3) dronabinol (10 mg)-placebo, and (4) hydromorphone (4 mg)-dronabinol (10 mg).
9 rticipants received (1) placebo-placebo, (2) hydromorphone (4 mg)-placebo; (3) dronabinol (10 mg)-pla
10 e disorder received combinations of placebo, hydromorphone (4 mg; oral), and dronabinol (2.5 mg, 5.0
11  derivatives of naltrexone, oxymorphone, and hydromorphone (4-9).
12 nans derived from naloxone, oxymorphone, and hydromorphone (7a-k) were synthesized and evaluated for
13 nt dose-effect relationship of dronabinol on hydromorphone across all measures was not observed.
14 ncrease in cyanide generation was seen after hydromorphone administration and this increase was block
15 ale (VAS; bipolar) score after intramuscular hydromorphone administration.
16 oderate adverse events than both placebo and hydromorphone alone.
17                        Little enhancement of hydromorphone analgesia by dronabinol was observed on ev
18                         The finding that the hydromorphone analogues (8, 9) were full mu agonists and
19  202 participants; 100 randomized to receive hydromorphone and 102 to diacetylmorphine.
20 buse liability, and cognitive performance of hydromorphone and oral delta-9-tetrahydrocannabinol (THC
21 d analgesic and drug effects of oral opioid (hydromorphone) and delta-9-tetrahydrocannabinol (dronabi
22 260 to methadone (dispensed for pain), 90 to hydromorphone, and 63 to morphine compared with 25 710 e
23 pioids, with tramadol, oxycodone, methadone, hydromorphone, and morphine being more commonly dispense
24  to detect oxycodone, hydrocodone, fentanyl, hydromorphone, and morphine both individually and as mix
25 ntoprazole; a limited rescue prescription of hydromorphone; and a patient educational infographic.
26  to receive intrathecal fentanyl or systemic hydromorphone at the first request for analgesia.
27   Intraoperative fentanyl and intraoperative hydromorphone average effect site concentration estimate
28 morphone+dronabinol 2.5 mg modestly enhanced hydromorphone-based analgesia and hydromorphone + dronab
29 cond-generation approach to the synthesis of hydromorphone by oxidative dearomatization/Diels-Alder c
30  whom it is contraindicated or unsuccessful, hydromorphone could be offered as an alternative.
31               Among the ligands studied, the hydromorphone-derived 4-chlorophenylpyridomorphinan 7h w
32 sorder (N = 82) were exposed to a cumulative hydromorphone dosing procedure, during which they comple
33 fects, and hydromorphone+dronabinol 5 mg and hydromorphone + dronabinol 10 mg produced AEs.
34               Analgesia only improved in the hydromorphone + dronabinol 2.5 mg condition.
35                                              Hydromorphone + dronabinol 2.5 mg showed the lowest and
36 y enhanced hydromorphone-based analgesia and hydromorphone + dronabinol 5 mg and 10 mg increased risk
37 d more mild adverse events than placebo, but hydromorphone + dronabinol produced more moderate advers
38                                              Hydromorphone+dronabinol 10 mg produced a high rate of d
39                                Overall, only hydromorphone+dronabinol 2.5 mg modestly enhanced hydrom
40 oduced a high rate of dysphoric effects, and hydromorphone+dronabinol 5 mg and hydromorphone + dronab
41 ne + dronabinol 2.5 mg showed the lowest and hydromorphone+dronabinol 5 mg showed the highest risk fo
42  response to NMDA similar to cyanide and the hydromorphone effect was blocked by cyanide scavengers.
43 produced immediate and sustained blockade of hydromorphone effects (liking maximum effect, CAM2038, 2
44                                              Hydromorphone enhanced the response to NMDA similar to c
45 n opioid analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphine, and tramadol.
46 ean differences between diacetylmorphine and hydromorphone for the ITT and PP analyses were reported.
47 idomorphinans possessing the oxymorphone and hydromorphone framework displayed nearly equal binding a
48 ship with the injection medication, 5 in the hydromorphone group and 24 in the diacetylmorphine group
49      To determine whether cyanide release by hydromorphone has functional significance in a neuronal
50                                         Only hydromorphone impaired cognitive performance.
51 ble to the analgesia from a moderate dose of hydromorphone in previous published experimental studies
52 dipipanone, morphine, diamorphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentaz
53 gnificantly increased by mu-opiate agonists (hydromorphone, morphine) and blocked by naloxone.
54  targeted by the Safer Opioid Supply policy (hydromorphone, morphine, oxycodone, and fentanyl); opioi
55 a Drug Effect visual analog scale during the hydromorphone-only condition) and nonresponders.
56          In contrast to methylnaltrexone and hydromorphone, oxycodone and hydrocodone do not interact
57 (all opioids, including morphine, methadone, hydromorphone, oxycodone, tapentadol, fentanyl, sufentan
58 d opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone, and codeine.
59                            Methylnaltrexone, hydromorphone, oxymorphone, and meptazinol were identifi
60     No serious adverse events were reported; hydromorphone produced more mild adverse events than pla
61 ence to suggest noninferiority of injectable hydromorphone relative to diacetylmorphine for long-term
62 ttenuated changes in subjective responses to hydromorphone relative to other participants, despite eq
63                   Systemic administration of hydromorphone to rats increased brain cyanide levels by
64 ed to receive injectable diacetylmorphine or hydromorphone (up to 3 times daily) for 6 months under s
65 responses to cumulative dosing of parenteral hydromorphone, versus placebo, in persons without a hist
66           The second-generation synthesis of hydromorphone was completed in both enantiomeric series.
67 ormal synthesis of the natural enantiomer of hydromorphone was completed.
68                            Noninferiority of hydromorphone was confirmed in the PP analysis (-1.44; 9
69 d intraoperative fentanyl and intraoperative hydromorphone were both associated with reduced maximum
70 s infusion narcotics (fentanyl, morphine, or hydromorphone) were used more frequently among patients
71 sia, received opioids other than fentanyl or hydromorphone, were admitted to the intensive care unit,